Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-generation ALK inhibitor, available in Europe ...
The US is currently overhauling its ATC infrastructure and replacing various outdated systems, even if those systems still ...
This year’s tech entrepreneurs are tailoring software and hardware to deliver more efficient and affordable solutions for ...
An international team led by University of Manchester scientists has created the most detailed picture yet of how genetic differences shape the way the human eye works. The breakthrough could help ...
Despite it being over a year since the release of the Garmin Fenix 8, the older Epix and Epix Pro remain two of the best alternatives. The brand consolidated its lineup considerably with the Fenix 8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results